Results 101 to 110 of about 5,054 (206)

Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis: a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study

, 2018
BACKGROUND: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel
Hsia, Elizabeth C, Boehncke, Wolf-Henning, Dong, Bin, Hsia, Elizabeth C., Wang, Yuhua, Barchuk, William, Xu, Xie L, Zhuang, Yanli, Deodhar, Atul, Gottlieb, Alice B, Xu, Xie L., CNTO1959PSA2001 Study Group   +11 more
core   +1 more source

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 9, Page 1490-1501, September 2026.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, on behalf of The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source

Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database [PDF]

BackgroundRisankizumab and guselkumab are two leading interleukin-23 (IL-23) inhibitors for treating immune-mediated inflammatory diseases. While effective, a direct comparison of their real-world safety profiles is lacking.
Fan, Yihong, Changbo Sun, Honggang Jiang, Yongyi Xu, Jiang, Honggang, Wang, Shiyi, Jing Ding, Hangjuan Lin, Yihong Fan, Lin, Hangjuan, Ding, Jing, Xudong Zhang, Sun, Changbo, Shiyi Wang, Zhang, Xudong, Xu, Yongyi   +15 more
core   +1 more source

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 9, Page 1449-1459, September 2026.
Dermatologists worldwide reached consensus on criteria for dose reduction (DR) of biologics for psoriasis resulting in a DR algorithm for adalimumab, etanercept and ustekinumab. DR of IL‐17 and IL‐23 inhibitors was deemed feasible as well. This first international consensus provides essential information for uptake of biologic DR for psoriasis globally.
C. A. M. van Riel, W.‐H. Boehncke, J. L. W. Lambert, P. I. Spuls, L. S. van der Schoot, I. van Ee, E. M. G. J. de Jong, J. M. P. A. van den Reek, on behalf of the eDelphi consortium, M. Elkalioby, L. Fianen, L. Linhares Leite, C. Boesjes, S. Mahil, M. Franco, F. Valenzuela, C. Chaiyabutr, M. A. Lorna, F. Frez, O. Zargari, T. Hillary, H. Oon, L. Skov, M. Gupta, E. Sotiriou, N. Nguyen Loft, R. Ceovic, K. M. G. Klaassen, J. Wikström, C. Zachariae, P. Asawanonda, R. Vender, A. Carvalho, J. Song, C. Lan, J.‐T. Maul, D. Jullien, B. Hidalgo‐Matlock, A. Duvetorp, M. Gkini, D. Ioannidis, W. Veldkamp, J. Hugo, J. Barboza, A. Carugno, A. Londoño‐García, L. Schneller‐Pavelescu Apetrei, M. Ferran, F. Lafuente Urrez, N. Merino, M. Llamas Velasco, L. Puig, M. Bourcier, M. Perez Ferriols, T. Leonidze, D. Armijo, A. Eylenbosch, M. B. A. van Doorn, P. P. M. van Lumig, P. Ghislain, A. Nast, S. Lanssens, E. Sonkoly, D. J. Hijnen, E. M. Baerveldt, P. Gisondi, M. Tjioe, I. Haeck, K. Agerberg, Y. Okubo   +69 more
wiley   +1 more source

Durability of response to icotrokinra for high‐impact site psoriasis: 1‐year ICONIC‐TOTAL findings

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 9, Page 1502-1514, September 2026.
Participants with at least moderate scalp, genital or hand/foot psoriasis receiving once‐daily oral icotrokinra achieved high, durable rates of overall and high‐impact site psoriasis clearance, showed substantial nail psoriasis improvement and exhibited no safety signals through 1 year, supporting icotrokinra use for long‐term management of high‐impact
Richard B. Warren, Melinda Gooderham, Edward Lain, Robert Bissonnette, Yu‐Huei Huang, Julien Ringuet, Matthias Hoffmann, Andreas Pinter, Joseph F. Merola, Jessica H. Rubens, Dorothy Fan, Ming‐Chun Hsu, Shu Li, Ya‐Wen Yang, Cynthia M. C. DeKlotz, Eingun James Song   +15 more
wiley   +1 more source

Long‐Term Effect of 2 Years of Persistent Guselkumab Therapy on Disease Severity and Patient‐Reported Outcomes in the CorEvitas Psoriasis Registry

Dermatologic Therapy
Background Guselkumab, an IL‐23 inhibitor, improved disease activity through five years in clinical trials of patients with moderate to severe plaque psoriasis.
Bruce E. Strober, April W. Armstrong, Timothy Fitzgerald, Katelyn Rowland, Olivia Choi, Daphne Chan, Jud C. Janak, Maya Marchese, Rachel E. Teneralli, Hyung-Joo Kang, Alvin H. Li, Steven R. Feldman   +11 more
doaj   +1 more source

Drug‐Induced Vitiligo: FDA Adverse Events Reporting System (FAERS) and Canada Vigilance Adverse Reaction (CAVR) Database Analysis and Literature Review

Journal of Cosmetic Dermatology, Volume 25, Issue 9, September 2026.
ABSTRACT Background Vitiligo is a common chronic acquired pigmentation disease, that usually occurs with an asymptomatic whitish patch or macule. Although previous studies have reported several cases of drug‐induced vitiligo, there are few comprehensive studies determining the drugs that induce vitiligo.
Yuhao Li, Yi Ou, Luyue Chang, Ruiyao Wang, Xinyi Shao, Jingbo Zhang, Jin Chen   +6 more
wiley   +1 more source

Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment

Journal of Inflammation Research
Xiuqing Yuan,1,* Tiantian Xin,1,* Huanhuan Yu,1 Jian Huang,2 Yaohan Xu,1 Caixin Ou,1 Yongfeng Chen1 1Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong Province, People’s Republic of China ...
Yuan X, Xin T, Yu H, Huang J, Xu Y, Ou C, Chen Y   +6 more
doaj  

The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study

Rheumatology and Therapy
Introduction Guselkumab is an interleukin-23 (IL-23) inhibitor licensed for the treatment of psoriatic arthritis (PsA). This study aimed to evaluate the 6-month effectiveness of guselkumab in patients with PsA in a “real-life” multicentre patient cohort.
Piero Ruscitti, Giulia Cataldi, Martina Gentile, Alice Dionisi, Paola Volpe, Annacarla Finucci, Lucrezia Verardi, Claudia Di Muzio, Noemi Italiano, Eleonora Celletti, Myriam Di Penta, Ilenia Di Cola, Alessandra Marrelli, Alessia Alfonsi, Francesco Delle Monache, Francesco Cipollone, Marco Gabini, Paola Cipriani   +17 more
doaj   +1 more source

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.

, 2022
BACKGROUND: The monoclonal antibody guselkumab is the first selective inhibitor of the interleukin-23 p19 subunit approved to treat adults with moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA). Given its recent approval for active
Ogdie, Alexis, Merola, Joseph F, Chakravarty, Soumya D, Mease, Philip J, Lin, Iris, McLean, Robert R, Kavanaugh, Arthur, Shiff, Natalie J, Malley, Wendi, Spitzer, Rebecca L   +9 more
core